This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Epocrates Feeds Physicians' "App"etites For Consumable Content

WATERTOWN, Mass., June 19, 2013 (GLOBE NEWSWIRE) -- As the provider of the top medical app for U.S. physicians, Epocrates, Inc., an athenahealth company (Nasdaq:ATHN), serves as the conduit for organizations to deliver succinct and actionable content to clinicians at the point of care. The company has expanded collaborations with three industry-leading organizations— Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality (AHRQ) and National Comprehensive Cancer Network ® (NCCN®)—to ensure valuable content is getting into the hands of the more than one million healthcare professionals in the Epocrates member network:
  • CDC works with Epocrates to educate physicians on topics such as hepatitis screening for baby boomers, emergency response to blast injuries, immunization updates, emerging resistant bacteria and local disease outbreaks. Epocrates can micro-target alerts to clinicians by region or specialty to ensure that the most relevant content is being received in a digestible mobile format.

CDC has also hand-selected patient education handouts to be hosted on the Epocrates online product for clinicians to conveniently print for or email to patients before leaving the office. Popular patient-friendly handout topics include weight management and sexually transmitted infections.
  • AHRQ provides a way for health professionals to access up-to-date information through the National Guideline Clearinghouse and issues comparative effectiveness reports that provide a basis for sound clinical decisions. Since clinicians are accustomed to relying on Epocrates, it is an organic extension for AHRQ's information to be readily available in the application. To date in 2013, Epocrates has selected more than 35 guidelines to be featured via its targeted DocAlert messaging system, delivering a total of 5,306,920 messages to clinicians' mobile devices. The timely and convenient delivery of these actionable guidelines has helped impact patient treatment in areas such as GERD, drug allergy and cancer screening.

Additionally, the popular AHRQ electronic preventive services selector tool (EPSS) is conveniently accessible within the free Epocrates app.
  • Leveraging its expertise in translating complex or extensive information into a succinct, user-friendly format, Epocrates recently expanded its free app based on the industry-leading NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ). Oncologists and hematologists can quickly and intuitively navigate select NCCN Guidelines for prostate, breast and colon cancers, with additional tumor types forthcoming.

Created specifically for mobile devices, the four star-rated iPhone app provides quick access to NCCN Guideline content with minimum steps.

"Epocrates knows how to present information in a digestible format and has made the NCCN Guidelines tremendously easy to use," said Dr. Russell Pachynski of Palo Alto, Calif. "What can I say — they have a secret sauce that works. I know if it comes from Epocrates, it will have all the key info that I need and will be highly relevant to my practice."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs